Harvey D. Homan has wide-ranging experience developing and growing businesses in the consumer health, pharmaceutical and medical device industries – both in the U.S. and Europe – by driving innovation in product portfolio development and business modeling. Throughout his career, Dr. Homan has leveraged his scientific background and business acumen to successfully develop and commercialize hundreds of products, from invention through R&D, regulatory, clinical and marketing phases. He also has led numerous in-licenses and product partnerships. As CEO of Ingenion Medical Limited, SR Holding 1 Co, Urovalve, Inc. and Linguagen Corp., Dr. Homan has led companies from formations in USA and UK through marketing authorization.
With the U.K.’s The Boots Company, Dr. Homan led all scientific, medical, regulatory and product-related functions for start-up of the new consumer-focused Boots Healthcare International, with teams in the UK, France and Germany. He played a leading role in building a new Division to > £500 million revenue in, including leadership of the integration of R&D and all scientific, medical and regulatory functions for two major acquisitions; product acquisitions and development partnerships with European, U.S., Indian and Japanese companies. During his last year, on assignment from the Boots chairman, he headed Corporate Development and Innovation, where he led analysis of international best practices that revealed needed process and organizational changes and he coached executives and board members in value creation through innovation. Starting with Sterling Drug Inc., he rapidly progressed through clinical science and marketing/sales executive roles to leadership of R&D, regulatory and clinical affairs for Sterling Health Europe, managing the global new product portfolio and developing innovative approaches to product development.
Dr. Homan holds a MBA, Marketing, from New York University, and a Ph.D. in Pharmacology from the University of Georgia.